BillionToOne, Inc. (NASDAQ:BLLN) filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing balance sheet data, share counts, and operational details for the third quarter.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $561,512 thousand as of September 30, 2026, compared to $495,97[x] thousand as of December 31, 2025, according to the filing.
  • Share count: As of November 2, 2026, there were 43,272,198 shares of Class A common stock and 4,502,650 shares of Class B common stock outstanding, each with a par value of $0.00001 per share.
  • Filer classification: The company identified itself as a non-accelerated filer and an emerging growth company under Rule 12b-2 of the Exchange Act.
  • Material weakness disclosure: The filing references the company's ability to remediate material weaknesses in its internal control over financial reporting as a forward-looking risk factor.
  • Exchange listing: Class A common stock trades on The Nasdaq Stock Market LLC under the symbol BLLN.
  • UNITY Fetal Antigen CTA: The filing references the potential for the company's UNITY Fetal Antigen CTA to become "the first non-invasive prenatal test (NIPT) to have a companion diagnostics indication pending," characterizing this as a forward-looking statement subject to its cautionary language.

BillionToOne's September 2026 Quarterly Disclosures: Financials, Share Structure, and Key Risk Factors

BillionToOne, Inc., a Delaware-incorporated molecular diagnostics company headquartered at 1035 O'Brien Drive, Menlo Park, CA 94025, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing covers Part I financial statements, management's discussion and analysis, and market risk and controls disclosures, as well as Part II legal and other information, according to the document.

The balance sheet as of September 30, 2026, reported cash and cash equivalents of $561,512 thousand. The corresponding figure as of December 31, 2025, appears partially in the source text as $495,97[x] thousand, with the final digit not fully legible in the provided filing extract. The company's share structure as of November 2, 2026, comprised 43,272,198 Class A shares and 4,502,650 Class B shares, both carrying a par value of $0.00001 per share, the filing stated.

The filing contains a range of forward-looking statements, which the company cautioned "are subject to a number of risks, uncertainties, and assumptions." Among topics addressed in the forward-looking statements are the company's reimbursement strategy, the ongoing Johnson and Johnson AZALEA Phase 3 clinical trial, expansion into prenatal and oncology markets, and the remediation of previously identified material weaknesses in internal control over financial reporting. The company stated it "undertake[s] no obligation to update any of these forward-looking statements for any reason after the date of this Quarterly Report... except as required by law."

What Was Disclosed

BillionToOne filed a Form 10-Q for Q3 2026, reporting cash of $561,512 thousand, a combined share count of approximately 47.8 million across two classes, emerging growth company status, and a series of forward-looking risk factors related to its diagnostics business.